Grazax Phase III pediatric trial encouraging
Grazax, the allergy immunotherapy developed by Schering-Plough and ALK-Abello, showed a 28% reduction in hay fever symptoms during its Phase III pediatric trial. According to Denmark-based ALK-Abello, the therapy led to a 64% reduction in the combined asthma symptom score as well. The previous European trial of Grazax displayed positive clinical effect. A Grazax pediatric registration application is currently under review in Europe.
- Novavax’s vaccine candidate works fine in trial’s second phase
- Intercell IC51 vaccine reflects positive data in Phase II
- Iomai immunostimulant adjuvant patch trial positive
- Trial results for AMAG iron replacement therapy favourable
